Press Releases

Eli Lilly and Company today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ingredient (API) facility, the third of four new U.S. sites Lilly plans to announce, will produce small molecule synthetic and peptide medicines. Importantly, the site will be among those that will manufacture orforglipron, Lilly's first oral, small molecule GLP-1 receptor agonist, which t

Pillar Biosciences and AstraZeneca today announced an expansion of their existing laboratory access program for NGS-based kitted liquid biopsy tumor profiling to include China. This expanded collaboration aims to deliver rapid, cost-effective, and clinically actionable genomic insights through liquid biopsy testing. By increasing the local availability of plasma-based tumor profiling at leading clinical laboratories in China, the partnership seeks to accelerate diagnostic turnaround

GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first recombinant anthrax vaccine. The product, jointly developed by the Korea Disease Control and Prevention Agency (KDCA) and GC Biopharma, was granted regulatory approval in April as Korea's 39th locally developed new drug. The initial supply will be delivered to the KDCA for national stockpiling, supporting public health preparedness aga

Lightbeam Health Solutions, the proven, AI-enabled solutions and services leader in population health management, today announced its acquisition of Syntax Health, an enterprise SaaS platform that streamlines contract modeling, incentive design, and payer-provider alignment. The addition of Syntax’s capabilities strengthens Lightbeam’s ability to support healthcare organizations navigating complex incentive structures and contract modeling while advancing more collaborative, data-

Shoulder Innovations, Inc, a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced a strategic partnership with Interventional Systems (INS), a developer of robotic solutions for minimally invasive surgery, to introduce a transformative shoulder-specific micro-robotic solution designed to further enhance shoulder surgical precision, workflow efficiency, and enable exciting, new clinical approaches in the total should

Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network designed to enhance speed, eff

COSCIENS Biopharma Inc, a life sciences company focused on pharmaceutical therapies, diagnostic products, and natural ingredients solutions, today announced that its wholly-owned subsidiary, Aeterna Zentaris GmbH, has entered into an exclusive distribution agreement with Wuzhou Drug International Trading Limited (“Wuzhou“) for the commercialization of Macrilen® (macimorelin) in Hong Kong, Macao, Singapore, and the Chinese provinces of Guangdong and Hainan. Under the

mAIbe and LenioBio are pleased to announce a new strategic collaboration aimed at accelerating the discovery and experimental validation of next-generation monoclonal antibodies. By combining mAIbe's AI-driven platform for antibody design and optimization with LenioBio's cell-free expression technology, this partnership brings together two complementary strengths to significantly enhance the design–build–test cycle. LenioBio's ultrafast, scalable ex

Imugene Ltd (ASX:IMU), a clinical-stage immuno-oncology company, and JW Therapeutics (Shanghai) Co., LTD (HKEX:2126), a leading biotechnology company focused on cell-based immunotherapies, today announced a co-development collaboration to evaluate the combination of Imugene’s oncolytic virus CF33-CD19 (onCARlytics) and JW’s Carteyva®—a CD19- directed autologous CAR-T cell therapy—for patients with advanced solid tumors. This collaboration includes preclin

Innova Therapeutics, a biopharmaceutical company, has announced that it has completed the acquisition of Enci Therapeutics. The acquisition includes Enci Therapeutics' main cancer therapeutic program, IVT-8086. The specific terms of the agreement and financial details regarding the acquisition between Innova Therapeutics and Enci Therapeutics have not been disclosed. IVT-8086 is a first-in-class, humanized monoclonal antibody (mAb) developed as a cancer therapeutic that targets